Skip to content
Events

Details

With the adoption of genomic tests growing, streamlining data curation and interpretation is more important than ever. Emedgene™ can help you unlock genomic insights and confidently scale your tertiary analysis workflows for rare disease genomics and other germline research applications with explainable AI (XAI) and workflow automation. Discover how this tertiary analysis software can speed up your germline analysis and provide you with multiple benefits today.

Watch this webinar to:

  • Understand how users are increasing their data interpretation efficiency by 2-5x
  • Learn what explainable AI (XAI) is and how you can reduce turn-around-time by 50-75%
  • See a live demo of the intuitive UI with an example workflow
  • Hear options to evaluate Emedgene with your own data – a fully supported experience with a genomic scientist and NGS workflow team

Speakers:

Miriam Fanjul
Staff Clinical Genomics Scientist
Illumina

Miriam Fanjul is a Staff Clinical Genomics Scientist at Illumina, specializing in the Tertiary Analysis Genomics Interpretation portfolio. In her role, she supports laboratories to implement tailored software solutions while acting as the Voice of the Customer to translate lab requirements into actionable product enhancements. Before joining Illumina, Miriam spent over six years as a Senior Medical Scientist at Victorian Clinical Genetic Services in Melbourne, Australia. There, she played a pivotal role in launching several NATA-accredited genomic tests and in validating numerous commercial tools for their fit-for-purpose in the clinical setting. Miriam holds a PhD in Cancer Biology & Genomics from the University of Oviedo, Spain and published numerous peer-reviewed articles in the fields of Cancer Biology, Neurogenetics and Clinical Genomics.

Orit Livnat-Levi
Emedgene Product Manager
Illumina

Orit Livnat Levi is the Associate Director of Informatics Product Management, focused on unlocking the interpretation bottleneck and enabling scale in the interpretation of Genetic Disease NGS data. She joined Illumina’s Emedgene team in 2019, and is passionate about applying AI and software technologies to transform tertiary analysis. She leads product strategy by translating customer needs and feedback into actionable development plans and ensuring that the resulting products meet or exceed customer expectations. Prior to Illumina, Orit spent over 15 years as a strategic marketer in AI, IOT and Bio-Tech startups. Orit holds an MBA with honors from NYU.
Fill Out Form to Access Webinar

Your email address is never shared with third parties.

Date & Time
16 Nov 2023
Location
Europe
Affiliation
Illumina
Presenter
Orit Livnat-Levi, Emedgene Product Manager and Miriam Fanjul, Staff Clinical Genomics Scientist
Topic
Complex disease genomics, Genetic & rare diseases, Pharmacogenomics, Precision health
Watch Now

Related Events

May 14
Comprehensive Genomic Profiling (CGP) advancing Precision Oncology
14 May 2026
Comprehensive Genomic Profiling (CGP) is redefining standard of care in precision oncology enabling nucleotide-level resolution of a tumor’s complete genomic landscape in a single comprehensive assay. Unlike iterative multiple single-gene tests, FISH-PCR-single gene or small hotspot panels, CGP uses advanced technologies such as next-generation sequencing to detect a broad range of genetic alterations, including mutations, copy number changes, structural variants and large genomic signatures (TMB, MSI, HRD).
View Event
May 28
The long sort of short: new insights into haplotype phasing with Illumina TruPath™ Genome
28 May 2026
Come and watch our presentation where you can learn about our solutions, services and how they might work for you.
View Event
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see emea.illumina.com/company/legal.html.

© 2026 Illumina, Inc. All rights reserved.